Manal Saleh
• Statistically
significant reductions in food noise scores from baseline were observed in
adults taking semaglutide injection within the first month of initiation and
through six months in the SIGNAL study1
• Oral
semaglutide was associated with about a 25% reduction from baseline in reported
average food noise scores over three months in the OCTANE study. Most adults
(86.4%) reported at least one treatment improvement2
• Food
noise is an emerging area of research in obesity care, with real-world studies
suggesting semaglutide may provide an additional patient-centered benefit
beyond weight
loss
Today, Novo Nordisk presented real-world
findings from the SIGNAL and OCTANE studies at ObesityWeek®️ 2026, looking at
how food noise scores changed for adults with overweight or obesity taking
Wegovy®️ injection or Wegovy®️ pill.1,2 Both retrospective cohort analyses used
de-identified patient data from the Ro telehealth platform and a validated
seven-item questionnaire to assess food noise, defined as persistent, intrusive
and unwanted thoughts about food.3
“Patients at our center often describe
persistent and intrusive thoughts about food, and that managing those thoughts
can take a toll on their day-to-day lives,” said Louis J. Aronne, MD, Director
of the Comprehensive Weight Control Center, Weill Cornell Medicine, and
co-author of the studies. “The SIGNAL and OCTANE findings showed that
semaglutide injection and oral semaglutide were associated with early
reductions in food noise in real-world studies. Looking forward, additional
research can help clarify the clinical relevance of such food noise and its
place in everyday obesity care.”
The two presented studies examined changes in
patient-reported food noise scores over time among adults with overweight or
obesity taking semaglutide in a real-world telehealth setting, using the
validated seven-item Ro Allison Indiana Dhurandhar–Food Noise Inventory
(RAID-FN) questionnaire, which measures persistent, intrusive and unwanted
thoughts about food.1,2
In the SIGNAL study, 26,213 treatment-naïve
adults with obesity or overweight with at least one weight-related condition
initiating semaglutide injection were followed for up to six months in a
real-world telehealth setting.1 The adjusted
mean baseline RAID-FN total score was 2.72 (95% CI 2.71, 2.74).1 Mean food
noise scores decreased within the first month, with an adjusted mean change
from baseline of -0.42 points (95% CI -0.43, -0.41).1 The greatest reductions
were observed during the first three months, and reductions were maintained
through month 6, when the adjusted mean change from baseline was -0.72 points (95% CI: -0.74 to -0.70).1
In the OCTANE study, adults initiating oral
semaglutide reported a statistically significant reduction in average food
noise scores over 3 months, reducing by ~25% from baseline (total RAID-FN score
2.8 to 2.1 (p<0.001)).2 At program entry, participants’ most commonly
reported treatment goals were to lose weight (98.0%), improve general physical
health (76.5%), and increase confidence in their appearance (54.5%).¹
Participants also commonly reported weight-related impacts on confidence,
clothing, sense of self and energy.2 At three months, 86.4% reported at least
one treatment improvement, including better-fitting clothing (67.5%), healthier
eating (51.6%), more physical activity (26.8%), more energy during the day
(26.6%), improved mood (21.7%), fewer alcohol cravings (18.8%) and better sleep
(18.6%).
“As
GLP-1 medicines, like Wegovy®️, become more widely used and discussed, many
people have asked about their impact on food noise as they think about
treatment,” said Michelle Skinner Moore, PharmD, MBA, interim head of clinical
development, medical and regulatory affairs and vice president, medical affairs
at Novo. “While food noise remains an emerging area of research, at Novo, we
are working to advance the science of obesity and broaden understanding beyond
changes on the scale. These real-world findings from the SIGNAL and OCTANE
studies, conducted in partnership with Ro, contribute to our efforts to better
understand the lived experiences of people with obesity and the outcomes they
say matter to them.”
Real-world evidence can complement randomized
controlled trials, which are the gold standard for evaluating a treatment’s
safety and efficacy.4 Real-world studies evaluate associations and cannot
determine causality. Limitations of the
SIGNAL and OCTANE studies include: variable timing and completeness of data
being collected during routine telehealth care; potential bias associated with
self-reported data; possible selection bias resulting from the treatmentpersistence
requirement; and limited generalizability to the broader population.
It is important to note that semaglutide
injection 2.4 mg and semaglutide tablets 25 mg contain a Boxed Warning for
possible thyroid tumors, including cancer, and should not be used in those with
a personal or family history of medullary thyroid carcinoma (MTC) or Multiple
Endocrine Neoplasia syndrome type 2 (MEN 2). The most common side effects
include nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain,
changes in skin sensations, headache, tiredness (fatigue), upset stomach,
dizziness, feeling bloated, belching, low blood sugar in people with type 2
diabetes, gas, stomach flu, heartburn, and hair loss.

-extra_large.jpg&w=3840&q=75)
-large.jpg)
-large.jpg)
-large.jpg)

-large.jpg)


-large.jpg)

كن أول من يشارك رأيه
ابدأ النقاش حول هذه القصة.